fbpx

First Medical Food for Dietary Management of PKD Launched

First Medical Food for the Dietary Management of Polycystic Kidney Disease Launched

The first-of-its-kind product, named KetoCitraTM, is based on breakthrough research by University of California Santa Barbara professor Dr. Thomas Weimbs, a recognized leader in the Polycystic Kidney Disease (PKD) research field, and Dr. Jacob Torres, Head Researcher of Santa Barbara Nutrients (SBN).

Santa Barbara, California – December 6th, 2021

The patented technology underlying KetoCitraTM was initially developed by Dr. Weimbs and Dr. Torres at the University of California, Santa Barbara. They discovered that a combination of two  natural compounds – beta-hydroxybutyrate (BHB) and citrate – has a synergistic effect in halting  or slowing the progression of PKD in animal models.

With kidney health and safety as a priority during the product’s development, SBN worked with a premier group of advisors that included some of the leading scientists, medical doctors and  dietitians in the renal field worldwide.

“The launch of KetoCitraTM is a seminal moment for both Santa Barbara Nutrients and PKD  patients. Our focus is to bring hope to the millions of PKD patients around the world, and we  think KetoCitraTM has the potential to achieve that,” said Dr. Weimbs, President and Founder  of Santa Barbara Nutrients.

PKD is one of the most common, life-threatening genetic diseases, causing kidney enlargement  and function loss over time. The disease affects over 600,000 Americans and 13 million people  worldwide and is one of the leading causes of kidney failure requiring dialysis or kidney  transplantation. There is no cure.

About KetoCitra TM

The research by Dr. Weimbs and Dr. Torres showed that two natural compounds, beta hydroxybutyrate (BHB) and citric acid (citrate), can help the nutritional management of PKD by  addressing the metabolic abnormalities that manifest during the progression of the disease.

KetoCitraTM is specifically designed with these two ingredients in a formulation that also delivers  beneficial minerals and an alkaline load intended to support the balancing of urine pH. The  inclusion of calcium and magnesium helps to manage the dietary absorption of the renal  stressors oxalate and inorganic phosphate.

KetoCitraTM uses only ingredients that are generally recognized as safe (GRAS), is sodium- and  sugar-free and formulated to be kidney-safe when used as directed. As a medical food,  KetoCitraTM is to be taken under medical supervision. KetoCitraTM can be taken by itself but is  recommended to be taken in conjunction with specific dietary and lifestyle changes. Researchers at SBN have collaborated with experienced renal dietitians to create a dietary program called Ren.Nu that is administered by the non-profit RenAlign. Patients in the Ren.Nu  program, which launches in January 2022, learn to implement a plant-focused, kidney-safe  ketogenic diet, together with KetoCitraTM, in a sustainable way.

About Santa Barbara Nutrients, Inc.  

Santa Barbara Nutrients is a public benefit corporation incorporated in Delaware and  headquartered in Santa Barbara, California. The experienced SBN team is composed of kidney  researchers, patients, and other industry professionals dedicated to bringing to market novel  medical foods and other innovative products to help people with PKD and other renal diseases.

The company is committed to scientific and clinical research to develop science backed  products that support human health and address significant unmet medical needs.

For more information, please visit www.SantaBarbaraNutrients.com

Want to read more? https://www.news.ucsb.edu/2021/020480/ketocitra-here

Contact:

Email: Info@SantaBarbaraNutrients.com

Phone: 1+805-272-0029

Breakthrough Patent Related to Polycystic Kidney Disease (PKD)

Santa Barbara Nutrients’ Scientists Awarded Breakthrough Patent Related to Polycystic Kidney Disease

 

University of California Professor, Dr. Thomas Weimbs, a recognized leader in the Polycystic Kidney Disease (PKD) research field and Dr. Jacob Torres, Head Researcher of Santa Barbara Nutrients (SBN), identified distinct metabolic polycystic kidney disease mechanisms that can be addressed by the unique formulation of two food ingredients that are Generally Recognized as Safe (GRAS): beta-hydroxybutyrate (BHB) and citrate. SBN’s first product, KetoCitra™, is a medical food for the dietary management of PKD and will be launched this year. KetoCitra™ is intended to be used under medical supervision and is covered by this new patent.

 

About KetoCitra™

 

The research by Dr. Weimbs and Dr. Torres showed that two natural compounds, beta-hydroxybutyrate (BHB) and citric acid (citrate), can help the nutritional management of PKD by addressing the metabolic abnormalities that manifest during the progression of the disease. KetoCitra is specifically designed with these two ingredients in a formulation that also delivers beneficial minerals and an alkaline load intended to support the balancing of urine pH.  The inclusion of calcium and magnesium helps to manage the dietary absorption of the renal stressors oxalate and inorganic phosphate.KetoCitra uses only ingredients that are generally recognized as safe (GRAS), is sodium- and sugar-free and formulated to be kidney-safe when used as directed. As a medical food, KetoCitra is to be taken under medical supervision. KetoCitra can be taken by itself but is recommended to be taken in conjunction with specific dietary and lifestyle changes. Researchers at SBN have collaborated with experienced renal dietitians to create a dietary program called Ren.Nu that is administered by the non-profit RenAlign. Patients in the Ren.Nu program, which launches in January 2022, learn to implement a plant-focused, kidney-safe ketogenic diet, together with KetoCitra, in a sustainable way.

 

“We are pleased that the U.S. Patent Office has recognized our unique research in understanding a complex disease like PKD. This is an important step in our company’s effort to bring affordable products to market that can bring hope to millions of people with PKD around the world,” said Dr. Weimbs, President and Founder of Santa Barbara Nutrients.

 

To read the full press release, follow this link: https://www.prweb.com/…/santa_barbara…/prweb18206928.htm

 

Santa Barbara Nutrients’ Team Member Publishes Paper in American Society of Nephrology

A Patient Perspective on Genetic Testing for ADPKD

The Lack of Complete Genetic Information, Especially Early in the Course of the Disease, Is Harming Adult Autosomal Dominant Polycystic Kidney Disease (ADPKD) Patients

The Clinical Journal of the American Society of Nephrology published a paper by our own Santa Barbara Nutrients’ business development lead, Dwight Odland.

To read the full article, please visit: https://cjasn.asnjournals.org/content/16/5/671 

Santa Barbara Nutrients’ Members Featured as Co-Authors in Polycystic Kidney Disease (PKD) Report

Santa Barbara Nutrients’ Members Featured as Co-Authors in Polycystic Kidney Disease (PKD) Report

Santa Barbara Nutrients is honored to have three of our core team members, Thomas Weimbs, David Baron and Dwight Odland, in addition to two members of our Medical Advisory Board, Michal Mrug and Vicente Torres, featured as co-authors on this special report.

This report is the summary of an event where patients and many of the key opinion leaders, researchers, policy makers and nephrologists in the polycystic kidney disease field convened to discuss identification and implementation of a proposed core outcome set for future ADPKD clinical trials.

Thank you for all of your hard work on this important issue.

Click here for the story featured in the American Journal of Kidney Diseases:

Establishing a Core Outcome Set for Autosomal Dominant Polycystic Kidney Disease: Report of the Standardized Outcomes in Nephrology–Polycystic Kidney Disease (SONG-PKD) Consensus Workshop